Previously, we have shown a role of cytosolic NAD(P)H: quinone oxidoreductase 1 (NQO1) in the stabilization of p63 against 20S proteasomal degradation resulting in thinning of the epithelium and chemical-induced skin cancer (Oncogene (2011(Oncogene ( ) 30, 1098(Oncogene ( -1107. Current studies have demonstrated that NQO1 control of CCAATenhancer binding protein (C/EBPa) against 20S proteasomal degradation also contributes to the upregulation of p63 expression and protection. Western and immunohistochemistry analysis revealed that disruption of the NQO1 gene in mice and mouse keratinocytes led to degradation of C/EBPa and loss of p63 gene expression. p63 promoter mutagenesis, transfection and chromatin immunoprecipitation assays identified a C/EBPa-binding site between nucleotide position À185 and À174 that bound to C/ EBPa and upregulated p63 gene expression. Co-immunoprecipitation and immunoblot analysis demonstrated that 20S proteasomes directly interacted and degraded C/ EBPa. NQO1 direct interaction with C/EBPa led to stabilization of C/EBPa against 20S proteasomal degradation. NQO1 protection of C/EBPa required binding of NADH with NQO1. Exposure of skin and keratinocytes to the chemical stress agent benzo(a)pyrene led to induction of NQO1 and stabilization of C/EBPa protein, resulting in an increase in p63 RNA and protein in wildtype but not in NQO1À/À mice. Collectively, the current data combined with previous data suggest that stress induction of NQO1 through both stabilization of C/EBPa and increase in p63 and direct stabilization of p63 controls keratinocyte differentiation, leading to protection against chemical-induced skin carcinogenesis. The studies are significant as 2-4% human individuals are homozygous and 23% are heterozygous for the NQO1P187S mutation and might be susceptible to stress-induced skin diseases.
Introduction
Dicoumarol-inhibitable cytosolic NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with cytochrome P450 reductase and catalyzes two-electron reductive detoxification of quinones, leading to protection against oxidative stress, mutagenicity and carcinogenicity Ross, 2004; Vasiliou et al., 2006) . The NQO1 gene expression is induced along with other phase II enzyme genes in response to xenobiotics and antioxidants (Kaspar et al., 2009 ). This provides protection for cells against oxidative stress and neoplasia. It is reported that diverse chemicals with the property to induce NQO1 and other enzymes block carcinogenesis (Zhang et al., 1994) . NQO1À/À mice exhibited significantly increased sensitivity to skin carcinogenesis in response to benzo(a)pyrene and 7,12-Dimethylbenz(a)anthracene (DMBA) (Long et al., 2001) . Studies also demonstrated that lower induction of p53 and decreased apoptosis contributed to chemical-induced skin carcinogenesis (Iskander et al., 2005) . The only other member of the NQO gene family NRH:quinone oxidoreductase 2 (NQO2) is also a cytosolic protein that metabolizes quinones and its derivatives . NQO2 is relatively less studied than NQO1, and its exact role in quinone metabolic detoxification and/or activation remains unknown. The human NQO1 gene is localized on chromosome 16q22 (Jaiswal et al., 1999) . A C-T polymorphism of the human NQO1 gene produces a praline-to-serine (P187S) substitution that leads to degradation of the enzyme (Traver et al., 1992; Siegel et al., 2001) . Individuals carrying both mutated genomic alleles are completely lacking in NQO1 activity, whereas heterozygous individuals have intermediate NQO1 activity compared with wild-type (WT) individuals (Siegel et al., 2001) . Approximately 2-4% individuals are homozygous and 20-25% are heterozygous for this mutation (Ross, 2004) .
p53, p63 and p73, each having multiple isoforms, belong to the p53 family of transcription factors (Moll and Slade, 2004; Pietsch et al., 2008) . These factors contribute various effects on downstream regulators of cell-cycle progression and apoptosis. p63 is ubiquitously present. However, the role of p63 is most relevant in the development of the normal epithelium in skin (King and Weinberg, 2007) . p63-null mice die at or before birth, lacking skin and with profound limb underdevelopment, which can be partially rescued by returning p63 expression to the mice, suggesting the vital role(s) of p63 in skin differentiation (Mills et al., 1999) .
Recent studies have shown a role of NQO1 in the stabilization of p53 against 20S proteasome degradation (Asher et al., 2001; Gong et al., 2007) . This stabilization of p53 is independent of ubiquitination (Asher et al., 2002) . This function of NQO1 is in addition to its role in metabolism of quinone compounds as described above. NQO1 also stabilizes ornithine decarboxylase, tumor suppressor p33ING1b and AP1 factor c-Fos (Asher et al., 2005; Garate et al., 2008; Adler et al., 2010) . Studies have also shown that both B[a]P-induced NQO1 and NQO2 stabilize p53 against 20S proteasomal degradation and protect against chemical-induced skin carcinogenesis (Gong et al., 2007) . More recent studies have shown that NQO1 but not NQO2 stabilizes p63 against 20S proteasomal degradation, resulting in protection against thinning of the epithelium and chemical-induced skin cancer (Patrick et al., 2011) . These studies together suggest that NQO1 through stabilization of factors regulates biological processes, leading to cell growth and differentiation. This property along with the property to detoxify quinones and derivatives led to protection against chemical-induced carcinogenesis.
In this report, we have extended studies to further understand NQO1 regulation of p63, which contributes to normal development of the skin epithelium and protection against chemical-induced skin carcinogenesis. Disruption of the NQO1 gene in mice led to degradation of C/EBPa and loss of p63 gene expression. p63 promoter mutagenesis and chromatin immunoprecipitation (ChIP) assays identified the C/EBPa element that bound to C/EBPa and upregulated p63 gene expression. Co-immunoprecipitation analysis demonstrated that 20S and NQO1 both directly interacted with C/EBPa. 20S degraded C/EBPa, whereas NQO1 protected C/EBPa against 20S proteasomal degradation. Exposure to the environmental stressor benzo(a)pyrene, as well as antioxidant tert-butyl hydroquinone (t-BHQ) led to stabilization of the C/EBPa protein, resulting in increase in p63 RNA and protein in WT but not in NQO1À/À mice. Collectively, the data suggest that stress induction of NQO1 through both stabilization of C/EBPa and increase in p63 and direct stabilization of p63 controls keratinocyte differentiation, leading to normal skin development and possibly contribute to protection against chemical-induced skin carcinogenesis.
Results
As we have discovered in previous studies (Patrick et al., 2011) , p63 levels in tumor-derived NQO1-null keratinocyte cell lines were significantly lower than those found in WT cell lines (Figure 1a) . In an effort to determine the correlation between C/EBPa and p63 expression, we probed WT and NQO1-null (1À/À) skin tissue and keratinocyte cell lines with antibodies against C/EBPa and discovered that similar to p63, C/EBPa expression was indeed lowered in NQO1-null keratinocytes, and also in skin tissues obtained from NQO1-null mice. Immunohistochemistry studies of mouse skin tissues confirmed this downregulation of C/EBPa, showing substantially less staining in NQO1-null than in WT mouse epidermis (Figure 1b) . As NQO1 is known to have a role in the regulation of p63 expression, we investigated whether modulation of NQO1 is sufficient to regulate levels of C/EBPa protein as well. Overexpression of the NQO1 construct led to substantial upregulation of C/EBPa in WT tumor-derived mouse keratinoyctes, whereas knockdown of NQO1 through small-interfering RNA led to substantial downregulation of C/EBPa ( Figure 1c) . As NQO1 regulation of p63 is known to be partly due to protection of p63 protein from 20S proteasomal degradation, we investigated whether modulation of C/EBPa alone is sufficient to cause changes in p63 levels. Similar to NQO1 modulation, overexpression of C/EBPa constructs in keratinocytes led to upregulation of p63 levels, whereas specific knockdown of C/EBPa levels led to downregulation of p63 ( Figure 1d ). To further elucidate the ability of NQO1 and C/EBPa to directly regulate p63 levels, we transfected WT keratinocytes with the C/EBPa construct and tested whether knockdown of NQO1 would be sufficient to abnegate the effect on p63 upregulation. Overexpression caused upregulation of p63, which was downregulated in a dose-dependent manner when cells were simultaneously transfected with specific NQO1 small-interfering RNA (Figure 1e ).
To further investigate the mechanism of C/EBPa regulation of p63, we mapped the mouse p63 promoter using MATinspector (Genomatix Software, Munich, Germany) and ProSite software (Sigrist et al., 2010) , which yielded a number of putative C/EBPa sites upstream of the start ATG (Supplementary Figure S1) . We then cloned the proximal 5 0 untranslated region of p63 and produced luciferase constructs, which contained these putative sites to measure their regulating activity. Overexpression of C/EBPa in cells containing both the longest (2.3 kb) and the shortest (0.5 kb) promoter sequences showed that C/EBPa is indeed capable of significantly inducing p63 transcriptional activity, and that most of the C/EBPa-specific induction is capable of occurring in the absence of the first two putative C/EBPa-binding sites located at À384 and À271, respectively (Figure 2a ). To verify these results and more closely to determine which putative sites were in fact active in the p63 promoter, we performed ChIP assay on WT keratinocytes using primers specific for a number of putative C/EBPa-binding sites (Figure 2b) . Results indicated that only the À185-binding site showed activity. In addition, we transfected WT keratinocytes with constructs containing WT p63 promoter luciferase constructs and constructs, which were mutated to abolish the specific C/EBPa-binding sites and measured transcriptional activity after induction with NQO1 overexpression (white bars), as well as with C/EBPa overexpression (gray bars) (Figure 2c ). Results indicated that induction by NQO1 or by C/EBPa was only affected in the À185-binding site, indicating that only this site is active in keratinocytes. Further transcriptional studies have found that coexpression of NQO1 and C/EBPa led to an additive effect on p63 transcription (Figure 2d , left panels), suggesting that NQO1 upregulation of C/EBPa leads to enhanced C/EBPa effect on p63 promoter. In addition, studies including a Y127/129A NADH-binding mutant of NQO1, previously shown to have no upregulation effect on p63 (Patrick et al., 2011) compared with WT NQO1 showed that abolition of NQO1 binding with NADH is sufficient to negate its ability to cause C/EBPa-mediated upregulation of p63 transcription (Figure 2d , right panels). To determine the physiological effect on this system by known cell stressors, we performed studies using benzo[a]pyrene (B[a]P) and t-BHQ, known inducers of the Nrf2-NQO1 stress response pathway (Figure 2e ). Results indicated that in both control WT keratinocytes (transfected with only empty vector) and in cells transfected with C/EBPa expression vector, stress-induced upregulation of NQO1 caused increase in p63 transcriptional activity, with an additive effect on exogenous induction caused by C/EBPa overexpression. Finally, we investigated whether induction or inhibition of NQO1 activity through known NQO1-modulation agents B[a]P and dicoumarol were sufficient to modulate C/EBPa binding to the À185 site on the p63 promoter ( Figure 2f ). We found a dose-dependent ability of B[a]P to induce C/EBPa binding to this promoter site, and conversely we found a dose-dependent ability of NQO1 inhibition Homogenates from wild-type (WT) and NQO1À/À mice, along with lysates from tumor-derived keratinocytes, were separated on 10% SDS-PAGE gels and probed with antibodies against NQO1, C/EBPa, p63 and GAPDH. Bar graphs beneath blots represent densitometric analysis of C/EBPa expression levels. (b) p63 expression in skin tissue corresponds to C/EBPa expression in vivo. Skin from age-matched male 7-9-week-old mice were harvested and prepared for immunohistochemical study, and probed with antibodies against C/EBPa and p63. Expression of each protein is visualized as red area. (c) Modulation of NQO1 levels leads to corresponding modulation of C/EBPa and p63 levels in cells. WT mouse keratinocytes were transfected with pCDNA-NQO1-V5 (upper panels) or siRNA against NQO1 (lower panels). After 48 h, cells were harvested and lysates analyzed by SDS-PAGE and immunoblotting with indicated antibodies. (d) Modulation of C/EBPa leads to corresponding modulation of p63 levels in cells. WT mouse keratinocytes were transfected with pCDNA-C/EBPa-V5 (upper panels) or siRNA against C/EBPa (lower panels). After 48 h, cells were harvested and lysates immunoblotted. (e) C/EBPa control of p63 expression is downstream to NQO1 control of C/EBPa. WT mouse keratinocytes were transfected with pCDNA-C/EBPa-V5 and/or siRNA against NQO1. After 48 h, lysates were separated on SDS-PAGE, followed by immunoblotting and probing with indicated antibodies. Bar graph to the right represents densitometric analysis of C/EBPa and p63 expression. A full colour version of this figure is available at the Oncogene journal online.
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To elucidate the role of the 20S proteasomal complex in C/EBPa regulation, we performed studies with a known inhibitor of proteasomal activity MG-132 ( Figure 3a) . We found that inhibition of 20S proteasomal activity was sufficient to inhibit C/EBPa degradation in both WT and NQO1-null lines, suggesting that downregulation of the C/EBPa protein in NQO1-null keratinocytes is at least in part due to degradation of protein by proteasomal pathways. Next, we investigated whether the effect of proteasomal degradation was apparent when NQO1 was exogenously modulated. After NQO1 was inhibited through small-interfering RNA, protein levels of C/EBPa were downregulated, whereas this NQO1-mediated downregulation was mostly prevented after proteasomal inhibition with MG-132 ( Figure 3b ). To determine that the 20S (ubiquitin-independent) pathway is responsible for C/ EBPa depletion and not simply the 26S (ubiquitindependent) pathway, we performed in vitro degradation studies using in vitro translated recombinant C/EBPa protein incubated for increasing periods with purified 20S proteasome (Sigma). We found that C/EBPa rapidly degrades in the presence of 20S proteasomal complex ( Figure 3c ) and that therefore the ubiquitinindependent pathway is capable of regulating the degradation of C/EBPa protein. Further in vitro degradation studies using recombinant C/EBPa and NQO1 proteins incubated with purified 20S proteasomal complexes revealed that just as we previously discovered with p63 (Patrick et al., 2011) , while C/EBPa was Chromatin precipitation assay was performed on WT keratinocytes cultured under normal conditions, using PCR primers specific for four putative C/EBPa-binding sites. (c) Disruption of À185 C/EBPa-binding site alone is sufficient to compromise NQO1-and C/EBPa-mediated p63 promoter activation. WT mouse keratinocytes were transfected with p63 promoter constructs containing either WT or mutated versions of each putative C/EBPa-binding site along with overexpression of NQO1-V5 (white boxes) or C/EBPa-V5 (gray boxes) and analyzed for luciferase activity. The lysates were immunoblotted to show level of expression of NQO1-V5 and C/EBPa-V5. Bar graph represents p63 promoter activation. (d) WT but not mutant NQO1 and C/EBPa act in concert to regulate p63 promoter activity. Left panel, 0.5 Kb p63 promoter was transfected in WT mouse keratinocytes along with NQO1-V5 and/or C/EBPa-V5. Right panel, WT mouse keratinocytes were transfected with 0.5 Kb p63 promoter construct and WT or inactive Y127/129A mutant NQO1-V5 plasmid. The transfected cells were immunoblotted and analyzed for luciferase activity. (e) C/EBPa-mediated induction of p63 promoter activity is enhanced by chemical agents. WT mouse keratinocytes were transfected with p63 promoter construct and either control plasmid or C/EBPa-V5 plasmid and exposed to either vehicle control, benzopyrene (left panel), or tert-butylhydroquinone (right panel) and analyzed for luciferase activity and immunoblotted for NQO1 and C/EBPa. (f) C/EBPa binding to À185 C/EBPa-binding site on p63 promoter is modulated by known modulators of NQO1 activity. WT keratinocytes were exposed to either vehicle control, NQO1 inducer benzopyrene (top panel) or NQO1 inhibitor dicoumarol (bottom panel) for 12 h before ChIP assay was performed using PCR primers against the À185 C/EBPa-binding site.
NQO1 controls of C/EBPa and p63 BA Patrick and AK Jaiswal efficiently degraded in the presence of the 20S proteasome, this 20S-mediated degradation was counteracted in the presence of NQO1 and NADH (Figure 3d ). This suggested that NQO1 þ NADH are sufficient to directly oppose 20S-mediated proteolysis of C/EBPa. Further studies showed that addition of the NQO1 inhibitor dicoumarol was sufficient to abnegate NQO1-mediated protection of C/EBPa degradation by the proteasome (Figure 3e ). This also suggested that NADH-bound NQO1 is essentially required for its inhibitory activity against proteolytic degradation of C/EBPa as dicoumarol is known to compete with NADH binding with NQO1 (Gong et al., 2007) . To show in greater detail the necessity of NQO1 þ NADH in the protection of C/ EBPa, we performed in vitro degradation studies using NADH-binding mutated forms of NQO1. We found that the loss of NADH cofactor-binding capacity (by mutation of tyrosines at 127 or 129) in NQO1 significantly impaired its ability to prevent 20S-mediated degradation of recombinant C/EBPa (Figure 3f , Supplementary Figure S2) . In previous investigations, we noted that NQO1 containing the well-known C->T polymorphism (which causes NQO1 protein instability) lost its ability to prevent p63 degradation; the same effect is apparent in the case of C/EBPa in which degradation proceeds mostly unimpeded (Figure 3f ). It is noteworthy that addition of V5-tag to the C terminus of NQO1P187S led to stabilization of an otherwise unstable mutant protein that protected C/EBPa against 20S degradation (Supplementary Figure S2) . Therefore, it is the loss of mutant NQO1P187S protein and not the mutation itself that led to the inability of NQO1 to protect C/EBPa against 20S.
In an effort to determine whether the ability of NQO1 to directly oppose 20S-mediated degradation of C/EBPa is due to a direct interaction with either 20S proteasomal complex or C/EBPa, we performed several immunoprecipitation studies using both endogenously expressed and overexpressed proteins. We found that, similar to p63 and p53, C/EBPa is capable of interacting directly WT mouse keratinocytes were transfected with either control or NQO1-specific siRNA for 48 h, followed by incubation with vehicle or MG-132 for 6 h. Lysates were separated on SDS-PAGE and immunoblotted with indicated antibodies. (c) C/EBPa levels are strongly modulated by 20S proteasomal degradation. pcDNA-V5 was used in TnT in vitro translation to produce recombinant protein, which was incubated with 2 mg purified 20S proteasomal complex in degradation buffer for various time points. Reactions were halted by freezing and immediately separated through SDS-PAGE followed by immunoblot analysis. (d) NQO1 with cofactor NADH is sufficient to rescue C/EBPa levels from 20S proteasomal degradation. C/EBPa protein was incubated with purified 20S proteasomal complex along with vehicle, purified NQO1 or NQO1 with reduced NADH cofactor for 1 h before halting reaction. The mixtures were analyzed by SDS-PAGE/immunoblotting. (e) Inhibition of NQO1 disrupts NQO1-mediated protection of C/EBPa from 20S proteasomal degradation. In vitro degradation assay was performed as described in panel d, with addition of experimental group containing 100 mm dicoumarol. (f) WT but not NADH-binding mutant NQO1 is capable of protection of C/EBPa against purified 20S proteasomal degradation. In vitro degradation assay was performed against recombinant C/EBPa protein containing equal amounts of either WT recombinant NQO1 or various mutant NQO1 species.
BA Patrick and AK Jaiswal with both NQO1 (Figure 4a ) and with the 20S proteasome ( Figure 4b ). NQO1 is, as was reported previously, not found to interact directly with the 20S proteasome ( Figure 4c ). These results suggest that NQO1 protection of C/EBPa may be similar in nature to its protection of p53 and p63. We next investigated the effects of known environmental stressor/carcinogen benzo[a]pyrene (B[a]P) ( Figure 5 ) and NQO1-inducing agent t-BHQ (Supplementary Figure S3 ) to determine their effects on NQO1-mediated induction of C/EBPa and its role in p63 gene expression. Studies were performed in both in vivo and in vitro systems using adult WT and NQO1-null mice and tumor-derived keratinocyte cell lines from these mouse lines, respectively. We discovered that B[a]P induction of NQO1 was accompanied by induction of C/EBPa and p63 protein levels ( Figure 5) . Results of these studies confirmed that environmental and chemical agents may lead to C/EBPa overexpression downstream to NQO1 induction, and prompted our investigation of other NQO1-inducing agents. We found that antioxidant t-BHQ in a dose-and time-dependent manner induced NQO1 expression that led to stabilization of the C/EBPa protein and induction of C/EBPa target gene p63 expression (Supplementary Figure S3) . After having established C/EBPa transcriptional activation of p63, we used p63 induction as a marker of C/EBPa activity and assayed both p63 transcription product (through quantitative PCR) and p63 translation product (through western blot). We found that induction of NQO1 led to increased C/EBPa transcriptional activity (presumably by NQO1 rescue of C/EBPa from proteasomal degradation), and this increase was apparent in the later increase of p63 transcript and subsequent increase of the p63 protein.
Discussion
In previous studies, we have investigated the role of NQO1 in the protection of p53 and p63 against proteasomal degradation by ubiquitin-independent mechanisms (Gong et al., 2007; Patrick et al., 2011) . The role of NQO1 in the protection of these factors, as well as in the protection of others such as ODC and c-Fos, has established NQO1 as a physiologically relevant agent in transcription factor biology. In these studies, we expand the role of NQO1 modulation of transcription factor p63 to include a previously uninvestigated pathway by which NQO1 can exert regulation of p63 and therefore p63-dependent processes such as epithelial development.
After continuing studies of NQO1 regulation of p63 expression, we found that p63 transcription was decreased in NQO1-null relative to WT keratinocytes (Patrick et al., 2011) , and subsequently we expanded our line of research to investigate the cause of this downregulation further. We noted that C/EBPa expression NQO1 controls of C/EBPa and p63 BA Patrick and AK Jaiswal corresponded well with p63 expression in both tissues and cell lines and that manipulation of C/EBPa led to changes in p63 expression, which mirrored changes caused by manipulation of NQO1. Further investigation of the p63 promoter revealed putative C/EBPa-binding sites, which were investigated for transcriptional activity, leading to the discovery that similar to results found in human p63 (Higashikawa et al., 2007) , there is a physiologically active C/EBPa-binding site at the mouse p63 promoter. Identification of a putative site allowed us to characterize its inducibility with WT but not null NQO1, and show that its binding to p63 promoter is proportionate to NQO1 expression. These results help to establish a role of NQO1 in the positive regulation of p63 transcription through upregulation of C/EBPa, which can itself directly drive p63 promoter activity.
Our previous investigations of regulatory activities of NQO1 led to 20S (ubiquitin-independent) proteasomal degradation as a mediating factor in transcription factor degradation. Therefore, we looked to this same mechanism to explain how NQO1 may be protecting C/EBPa from depletion in WT systems. Our numerous in vitro degradation studies have shown that C/EBPa is in fact strongly degraded by 20S proteasomal complexes and that this degradation can be thwarted by the presence of NQO1. Furthermore, we discovered that like p53 and p63, NADH was an important parameter in the ability of NQO1 to exert this protective effect on C/EBPa against proteolysis due to 20S and that compromising the stability of NQO1 had consequences on C/EBPa stability against 20S-specific degradation. Furthermore, we investigated whether the characterized ability of NQO1 to bind directly to its target protein held true for C/EBPa. Studies involving both tagged NQO1 and C/EBPa, as well as endogenous protein studies in both WT and NQO1-null keratinocyte cell lines provided data, which support the hypothesis that NQO1 does in fact bind directly to C/EBPa and thereby directly prevents its depletion from cells by proteasomal degradation. This is important to our understanding of NQO1 in that it further elucidates its ability and tendency to directly interact with transcription factor proteins to facilitate their protection from 20S-mediated proteolysis. This, in addition to the necessity of NADH cofactor and WT genotype at P187 for protective activity, strongly indicates that NQO1 likely uses the same mechanism in the protection of the ever-expanding collection of transcription factors from degradation.
To determine the physiological relevance of C/EBPa in the NQO1-p63 axis, we investigated the effect of known NQO1-inducing agents, both environmental stressors such as benzo [a] pyrene and chemical inducers of NQO1 such as t-BHQ, on C/EBPa induction and transcriptional activity. In all cases of NQO1 induction, we found a dose-and time-dependent induction of C/EBPa, as well as a later induction of C/EBPa transcriptional activity at the p63 promoter, leading to induction of p63 protein levels. These studies further suggest that C/EBPa is an efficient mediator of NQO1 modulation of p63 expression in keratinocytes and that C/EBPa-mediated activation of p63 promoter and subsequent increase of p63 mRNA in keratinocytes is a common physiological response after NQO1 induction by multiple means and preceding the direct protection of p63 protein levels by NQO1.
Although it still seems that the primary mechanism for NQO1 modulation of p63 is through direct interaction and protection from ubiquitin-independent proteasomal degradation, there exists a secondary but significant pathway by which NQO1 and NADH mediate p63 expression in the epithelium. In our hypothetical model (Figure 6 ) in WT systems, NQO1 protection of C/EBPa leads to buildup in tissues, which ultimately leads to increased C/EBPa transcriptional activity at established transcription factor-binding sites on the p63 promoter and subsequent increase in p63 transcription, leading to an increase in p63 levels, which can either be degraded by default by 20S proteasome or be protected by NQO1 interaction, leading to p63 buildup and subsequent increase in p63-dependent pathways such as keratinocyte differentiation. In NQO1-deficient systems, the lack of NQO1 expression leads to a shift in the equilibrium between C/EBPa default degradation by 20S proteasome and protection, leading to increased C/EBPa proteolysis and subsequently decreased protein levels. The decreased C/EBPa protein levels leads to decreased transcriptional activity at the p63 promoter and thereby less p63 transcription. This decreased p63 transcription coupled with the lack of NQO1-mediated rescue of p63 protein from 20S proteasomal degradation lead to stark decrease in overall p63 levels and thereby decreases in p63-dependent pathways.
In summary, we demonstrated that NQO1 along with its cofactor NADH stabilizes C/EBPa against 20S proteasomal degradation. This resulted in transcriptional activation of p63. NQO1 stabilization of C/EBPa required NQO1 cofactor NADH and a direct interaction with C/EBPa. Chemical stress induced NQO1, leading to the stabilization of C/EBPa and increased transcription of p63. NQO1/C/EBPa-mediated transcriptional activation of p63 (current report) along with NQO1/NADH-mediated stabilization of p63 (Patrick et al., 2011) contributed to normal skin epithelium development and protection against chemical-induced skin cancer.
Materials and methods
Animals, cell culture, inhibitors, mutants and treatments C57BL/6 NQO1-null mice were derived by us as reported previously (Radjendirane et al., 1998) . Keratinocytes from these mice were derived from tumors induced by application of DMBA to the skin as described previously (Ahn et al., 2006) and subsequently cultured in Dulbecco's modified Eagle's medium/10% fatal bovine serum/1% antibiotics and subcultured 2-3 Â each week. WT mouse keratinocytes were transfected using Amaxa Nucleofector machine with cell linespecific reagents according to the manufacturer's recommendations (Lonza, Basel, Switzerland). The 20S proteasome complex inhibitor MG132 was obtained from Sigma (St Louis, MO, USA) and diluted in dimethyl sulfoxide to produce stocks. DNA transfections were performed using Effectene reagent (Qiagen, Valencia, CA, USA), and small-interfering RNA transfections were performed using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). Cell lines that were not lab-derived were obtained from ATCC (Manassas, VA, USA). Mutants of human NQO1 were produced using GeneTailor site-directed mutagenesis kit (Invitrogen) as reported previously (Patrick et al., 2011) according to the manufacturer's suggestions, using sequence provided by Figure 6 Hypothetical model of NQO1 control of C/EBPa stability to regulate p63 expression. In wild-type cells, wherein NQO1 is present, NQO1 is able to directly protect C/EBPa protein against 20S proteasome-mediated degradation, and thereby allow C/EBPa to upregulate p63 expression and p63-downstream processes, leading to keratinocyte differentiation. In NQO1-null cells, lack of NQO1 allows C/EBPa to be efficiently degraded by 20S proteasomal complex, thereby leading to lower steady-state levels of C/EBPa, and therefore lower steady-state activation of C/EBPa sites on p63 promoter and less p63 expression, finally resulting in decreased signaling through p63-downstream processes leading to less keratinocyte differentiation. A full colour version of this figure is available at the Oncogene journal online.
NQO1 controls of C/EBPa and p63 BA Patrick and AK Jaiswal Pubmed (NM_000903) to determine relevant residues from the previously cloned HuNQO1 vector, and all clones were subcloned into the pCDNA 3.1 vector for use.
Histology Seven-to-nine-week-old male WT and NQO1À/À mice were killed using isofluorane according to IACUC (Institutional Animal Care and Use Committee)-approved protocols, and dorsal skin areas were shaved with clippers and removed by surgery. The skin was fixed in a solution of formalin overnight at room temperature with gentle stirring, and brought to the University of Maryland Dermatopathology laboratory for embedding in paraffin blocks and microtomy, as well as mounting to charged slides and subsequent hematoxylin and eosin staining.
Western blot analysis
Cell lysates and tissue homogenates were homogenized/lysed in RIPA buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% deoxycholate, 1% NP-40, 1% Triton X-100, 1 mM PMSF and protease inhibitor cocktail (Roche, KonzernHauptsitz, Switzerland)) chilled on ice and clarified by centrifugation at B10 000 Â g. Protein concentration was estimated by the Bradford method with diluted Bio-Rad reagent (Bio-Rad, Hercules, CA, USA). SDS-PAGE analysis was performed as described previously (Gong et al., 2007) . Antibodies against NQO1 were derived in our laboratory as described previously (Radjendirane et al., 1998) ; antibodies against DNp63a (4A4 with quantitation of the prominent band at 51-55 kDa), C/EBPa (14AA) and glyceraldehyde phosphate dehydrogenase and protein A/G agarose bead slurry were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Enhanced chemiluminescent reagent was purchased from GE Healthcare (Piscataway, NJ, USA) and Pierce Biotechnology (Thermo Fisher Scientific, Rockford, IL, USA).
Immunoprecipitation
Cells were plated into 150 mm cell culture dishes and grown until 75% confluence before transfection. Forty-eight hours after transfection, dishes were washed in phosphate-buffered saline and scraped in RIPA buffer with protease inhibitor cocktail and rotated at 4 1C for 20 min before centrifuging at 14 000 r.p.m. for 10 min to pellet debris. The supernatant was quantified and brought to 2 mg/ml in RIPA and precleared with washed protein A/G-agarose beads (Santa Cruz Biotechnology) for 1 h at 4 1C, followed by bead removal and immunoprecipitation overnight with 1:100 20S core subunit antibody (Calbiochem, San Diego, CA, USA), 1:1000 V5 antibody (Invitrogen), or 1:100 flag antibody-conjugated agarose beads (Sigma). Endogenous immunoprecipitation (IP) studies were performed using the same antibodies as were used in western blot studies, at 1:100 concentration. The next day, fresh A/G-agarose beads were added for 2 h to bind antibodies, and samples were washed twice in RIPA buffer before boiling 5 min in 2 Â SDS loading buffer.
Quantitative PCR Cells were cultured in 10-cm dishes and harvested using RNeasy (Qiagen) to purify total RNA, and DNA degraded using Turbo DNA-free (Ambion, Austin, TX, USA). After confirming quality through spectrophotometry and on agarose gel, RNA (25-100 ng) was used as a template for qPCR with appropriate TaqMan probes (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocols, n ¼ 3 per group normalized against internal controls (Rox) and also external controls (GusB for mouse keratinocytes) on ABI 7500 real-time PCR system. In vitro translation and 20S proteasomal degradation of translated protein Proteins were translated from laboratory-generated plasmids using TnT in vitro translation kit (Promega, Madison, WI, USA) with cold (non-radioactive) methionine added. Purified 20S proteasomal complex was purchased from Sigma and dissolved in dimethyl sulfoxide. NQO1-V5 and pcDNA-C/ EBPa plasmid DNA were translated for 90 min at 30 1C, and 2 mg of this was incubated with 20S proteasome in degradation buffer (100 mmol/l Tris-Cl (pH 7.5), containing 150 mmol/l NaCl, 5 mmol/l MgCl 2 and 2 mmol/l DTT) as described previously (Gong et al., 2007) for various time points and quenched through freezing at À80 1C. Samples were separated on 12% SDS-PAGE and immunoblotted. Blots were probed with V5-HRP (to detect NQO1-V5), 20Sa5 and p63 (4A4-HRP) antibodies. In related experiments, in vitro translated NQO1 with or without NADH and NQO1 inhibitor dicoumarol were included and 20S degradation of p63 experiments repeated. Dicoumarol was dissolved in 3% NaOH in deionized water for use, and NADH was dissolved in degradation buffer.
Immunohistochemistry
All animals were killed with isofluorane vapors according to IACUC-approved protocols, and the skin was removed using scissors after shaving with cordless clippers to remove excess hairs. Shaved skin patches were fixed in formalin solution (Sigma) overnight and afterwards placed into cassettes and embedded in paraffin at the University of Maryland Dermatolopathology Laboratory. Paraffin blocks were sliced, and sections were affixed to charged slides. Slides were hydrated in xylene, 100% EtOH, 95, 90, 70, 30%, followed by peroxidase blocking with 3% H2O2/MeOH, Retrievagen antigen retrieval (BD Pharmingen, Mississauga, ON, Canada) at B95 1C using steam for 30 min and using the Vectastain ABC-AP kit (Vector Labs, Burlingame, CA, USA) with primary antibodies (1:500 C/EBPa 14AA) for 1 h in a dark humidified chamber, followed by staining with Vector Red Alkaline Phosphatase Substrate Kit I (Vector Labs), and hematoxylin counterstaining for 3 min, all according to manufacturer's recommendations (Sigma), followed by sealing under coverslips with aqueous Vectamount (Vector Labs). Slides were photographed using the Nikon Eclipse 80i upright microscope (Nikon, Nikon Instech Co., Chiyoda-ku, Tokyo) under Plan Apo 20 Â /0.75 DIC N2 WD 1.0 and Plan Apo 40 Â / 0.95 DIC M/N2 WD 0.14 objectives, and all fields were rotated as necessary to match. Nikon NIS-Elements BR 3.0 software was used with the microscope, along with DS-Fi1 bright-field camera. All slide photography was performed at room temperature, and all files saved as jpeg format with each field subjected to 'auto white balance' before capturing, with no other manipulation.
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